Hansa Biopharma divests its equity holding in Genovis
Proceeds to be used to further expedite development of Company’s pipelineLund, Sweden, April 15, 2019 – Hansa Biopharma AB (NASDAQ Stockholm: HNSA), the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, announced today that it has divested its entire equity stake in Genovis AB (NASDAQ Stockholm: GENO). The transaction generated gross proceeds of SEK 89 million (c.$9.6 million).The proceeds will be used as working capital not only to expedite further the clinical development program of imlifidase in transplant rejection and autoimmune diseases, but also to ramp